Literature DB >> 16381070

Non-inferiority trials: the 'at least as good as' criterion with dichotomous data.

Larry L Laster1, Mary F Johnson, Mitchell L Kotler.   

Abstract

The 'at least as good as' criterion, introduced by Laster and Johnson for a continuous response variate, is developed here for applications with dichotomous data. This approach is adaptive in nature, as the margin of non-inferiority is not taken as a fixed difference; it varies as a function of the positive control response. When the non-inferiority margin is referenced as a high fraction of the positive control response, the procedure is seen to be uniformly more efficient than the fixed margin approach, yielding smaller sample sizes when sizing non-inferiority trials under identically specified conditions. Extending this method to proportions is straightforward, but highlights special considerations in the design of non-inferiority trials versus superiority trials, including potential trade-offs in statistical efficiency and interpretability. Copyright 2005 John Wiley & Sons, Ltd.

Mesh:

Year:  2006        PMID: 16381070     DOI: 10.1002/sim.2476

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  6 in total

1.  Methods for equivalence and noninferiority testing.

Authors:  Gisela Tunes da Silva; Brent R Logan; John P Klein
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

Review 2.  Biosimilars: clinical interpretation and implications for drug development.

Authors:  Eduardo Mysler
Journal:  Curr Rheumatol Rep       Date:  2015-02       Impact factor: 4.592

Review 3.  Statistical Considerations of Food Allergy Prevention Studies.

Authors:  Henry T Bahnson; George du Toit; Gideon Lack
Journal:  J Allergy Clin Immunol Pract       Date:  2017 Mar - Apr

4.  Sample Size Estimation for Non-Inferiority Trials: Frequentist Approach versus Decision Theory Approach.

Authors:  A C Bouman; A J ten Cate-Hoek; B L T Ramaekers; M A Joore
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

5.  Effect of Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy on Local Recurrence and Survival: Long-term Results From the TARGIT-A Randomized Clinical Trial in Early Breast Cancer.

Authors:  Jayant S Vaidya; Max Bulsara; Christobel Saunders; Henrik Flyger; Jeffrey S Tobias; Tammy Corica; Samuele Massarut; Frederik Wenz; Steffi Pigorsch; Michael Alvarado; Michael Douek; Wolfgang Eiermann; Chris Brew-Graves; Norman Williams; Ingrid Potyka; Nicholas Roberts; Marcelle Bernstein; Douglas Brown; Elena Sperk; Siobhan Laws; Marc Sütterlin; Steinar Lundgren; Dennis Holmes; Lorenzo Vinante; Fernando Bozza; Montserrat Pazos; Magali Le Blanc-Onfroy; Günther Gruber; Wojciech Polkowski; Konstantin J Dedes; Marcus Niewald; Jens Blohmer; David McCready; Richard Hoefer; Pond Kelemen; Gloria Petralia; Mary Falzon; Michael Baum; David Joseph
Journal:  JAMA Oncol       Date:  2020-07-09       Impact factor: 31.777

6.  Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial.

Authors:  Jayant S Vaidya; Max Bulsara; Michael Baum; Frederik Wenz; Samuele Massarut; Steffi Pigorsch; Michael Alvarado; Michael Douek; Christobel Saunders; Henrik L Flyger; Wolfgang Eiermann; Chris Brew-Graves; Norman R Williams; Ingrid Potyka; Nicholas Roberts; Marcelle Bernstein; Douglas Brown; Elena Sperk; Siobhan Laws; Marc Sütterlin; Tammy Corica; Steinar Lundgren; Dennis Holmes; Lorenzo Vinante; Fernando Bozza; Montserrat Pazos; Magali Le Blanc-Onfroy; Günther Gruber; Wojciech Polkowski; Konstantin J Dedes; Marcus Niewald; Jens Blohmer; David McCready; Richard Hoefer; Pond Kelemen; Gloria Petralia; Mary Falzon; David J Joseph; Jeffrey S Tobias
Journal:  BMJ       Date:  2020-08-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.